Centogene N V Revenue Growth Rates (CNTG), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Centogene N v   (NASDAQ: CNTG)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

CNTG's Revenue Growth by Quarter and Year

Centogene N V 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CNTG Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December 54.32
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 54.32

CNTGs Annual Revenue
Centogene N V 's Revenue in the fiscal year 2023 $ 54.32 millions
Centogene N V 's Revenue in the fiscal year 2022 $ 53.17 millions
Centogene N V 's Revenue in the fiscal year 2021 $ 212.71 millions
Centogene N V 's Revenue in the fiscal year 2020 $ 87.75 millions
Centogene N V 's Revenue in the fiscal year 2019 $ 71.62 millions




CNTG Revenue fourth quarter 2023 Y/Y Growth Comment
Centogene N V showed record Revenue improvement in the fourth quarter 2023 with 2.16% from the fourth quarter 2023 2022, to $ 54.32 millions.

Looking into fourth quarter 2023 results within Medical Laboratories industry 18 other companies have achieved higher Revenue growth. While Centogene N V ' s Revenue increase of 2.16% ranks overall at the positon no. 2019 in the fourth quarter 2023.


CNTG Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December 2.16 % -75 % - -
3rd Quarter September - - -86.32 % 228.21 %
2nd Quarter June - 5.48 % -47.17 % -14.97 %
1st Quarter March - -3.4 % -54.85 % 9.7 %
FY   -29.22 % -69.02 % 187.64 % -

Financial Statements
Centogene N V 's fourth quarter 2023 Revenue $ 54.32 millions CNTG's Income Statement
Centogene N V 's fourth quarter 2022 Revenue $ 53.17 millions Quarterly CNTG's Income Statement


CNTG Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - - 1730.55 % -
3rd Quarter September - - 2.74 % 296.73 %
2nd Quarter June - 2.49 % -6.14 % -19.78 %
1st Quarter March - -94.53 % - -
FY (Year on Year)   -29.22 % -69.02 % 187.64 % -


Back to CNTG Growth rate Comparisons >> Back to CNTG Growth rate Comparisons >>


Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #19
Healthcare Sector #352
Overall #2019

Revenue Y/Y Growth Statistics
High Average Low
2.16 % -36.42 % -75 %
(Dec 31 2023)   (Dec 31 2022)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #19
Healthcare Sector #352
Overall #2019
Revenue Y/Y Growth Statistics
High Average Low
2.16 % -36.42 % -75 %
(Dec 31 2023)   (Dec 31 2022)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Centogene N V 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CNTG's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CNTG's IV. Quarter Q/Q Revenue Comment


Centogene N V 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Dec 31 2020)		 12 Months Ending
Cumulative Revenue 12 Months Ending $ 54.32 $ 53.17 $ 212.71 $ 87.75 $ 0.00
Y / Y Revenue Growth (TTM) 2.16 % -75 % 142.4 % 22.52 % -
Year on Year Revenue Growth Overall Ranking # 3880 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 2.16 % -75 % 142.4 % 22.52 % -
Seq. Revenue Growth (TTM) Overall Ranking # 3880 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
With 2.16% annual Revenue growth, Centogene N V would report a record annual Revenue improvement if the fiscal year would end on Dec 31 2023.

In the Healthcare sector 550 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3880.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 36
Healthcare Sector # 551
Overall # 3880

Revenue TTM Y/Y Growth Statistics
High Average Low
2.16 %
 -36.42 %
-75 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 36
Sector # 551
S&P 500 # 3880
Cumulative Revenue growth Comment
With 2.16% annual Revenue growth, Centogene N V would report a record annual Revenue improvement if the fiscal year would end on Dec 31 2023.

In the Healthcare sector 550 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3880.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 36
Healthcare Sector # 551
Overall # 3880

Revenue TTM Y/Y Growth Statistics
High Average Low
2.16 %
-36.42 %
-75 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 36
Sector # 551
S&P 500 # 3880




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CNTG's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue improvement for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Lifeloc Technologies Inc 3.78%$ 3.778 millions
Teladoc Health Inc 3.58%$ 3.578 millions
Iqvia Holdings Inc 3.45%$ 3.450 millions
Procaps Group S a 3.37%$ 3.373 millions
Astrazeneca Plc3.29%$ 3.292 millions
West Pharmaceutical Services Inc 3.22%$ 3.217 millions
Dentsply Sirona Inc 2.95%$ 2.950 millions
AnTix Holdings, Inc.2.93%$ 2.926 millions
Oculis Holding Ag2.90%$ 2.899 millions
Igm Biosciences Inc 2.81%$ 2.806 millions
Becton Dickinson And Company2.62%$ 2.617 millions
Cumberland Pharmaceuticals Inc 2.51%$ 2.514 millions
Prestige Consumer Healthcare Inc 2.33%$ 2.328 millions
Sanofi2.32%$ 2.324 millions
Stablecoin Development Corporation2.31%$ 2.306 millions
Amneal Pharmaceuticals Inc 2.30%$ 2.298 millions
Nevro Corp 2.25%$ 2.252 millions
Centogene N v 2.16%$ 2.161 millions
Teleflex Incorporated2.09%$ 2.094 millions
Taro Pharmaceutical Industries Ltd2.07%$ 2.070 millions
Standard Biotools Inc 2.05%$ 2.050 millions
Phibro Animal Health Corporation2.03%$ 2.032 millions
Icu Medical Inc1.94%$ 1.940 millions
Koninklijke Philips Nv1.92%$ 1.918 millions
Akebia Therapeutics Inc 1.84%$ 1.838 millions
Accelerate Diagnostics Inc 1.82%$ 1.816 millions
Atrion Corporation1.70%$ 1.701 millions
Amedisys Inc1.55%$ 1.552 millions
Abbott Laboratories1.49%$ 1.486 millions
Procyon Corporation1.36%$ 1.361 millions


About Centogene N V Revenue Growth Rates (CNTG), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Centogene N v (CIK 1757097).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001558370-24-008317
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Centogene N v ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.